Leap Therapeutics, Inc., a biotechnology company focused on developing targeted and immuno-oncology therapeutics, recently announced that their President and CEO, Douglas E. Onsi, will be participating in a fireside chat at the upcoming Piper Sandler 35th Annual Healthcare Conference in New York, NY.
The fireside chat, scheduled for Tuesday, November 28, 2023, at 8:00 a.m. Eastern Time, will provide an opportunity for Leap Therapeutics to share insights on their innovative approach to cancer treatment. As a company dedicated to developing therapeutics that target specific proteins involved in cancer progression, Leap Therapeutics has made significant progress in their clinical development programs.
One of their most advanced candidates is DKN-01, a humanized monoclonal antibody that targets the Dickkopf-1 (DKK1) protein. This candidate therapy is currently being evaluated in patients with esophagogastric, gynecologic, and colorectal cancers. Another promising candidate is FL-301, a humanized monoclonal antibody targeting Claudin18.2, which is being developed for patients with gastric and pancreatic cancer.
Leap Therapeutics also has several preclinical antibody programs in the pipeline, including targets such as Claudin18.2/CD137 and GDF15. These programs hold promise for future advancements in cancer therapeutics.
For those unable to attend the conference in-person, Leap Therapeutics will be providing a live webcast of the fireside chat on the Investors page of their website. A replay of the event will also be available for a limited time.
With a commitment to advancing the field of oncology and providing innovative treatment options for patients, Leap Therapeutics continues to make strides in the development of targeted and immuno-oncology therapeutics. For more information about Leap Therapeutics and their ongoing research and development programs, visit their website.
1. What is Leap Therapeutics focused on?
Leap Therapeutics is focused on developing targeted and immuno-oncology therapeutics.
2. What are their most advanced clinical candidates?
Their most advanced clinical candidate is DKN-01, a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein, which is being developed in patients with esophagogastric, gynecologic, and colorectal cancers. They also have FL-301, a humanized monoclonal antibody targeting Claudin18.2, in development for patients with gastric and pancreatic cancer.
3. What are their preclinical antibody programs?
Leap Therapeutics has preclinical antibody programs targeting Claudin18.2/CD137 and GDF15.
4. Where can I access the live webcast of the fireside chat?
The live webcast of the fireside chat can be accessed on the Investors page of Leap Therapeutics’ website at https://investors.leaptx.com/.